These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26102513)

  • 1. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
    Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
    PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
    Bhaumik S; Ahmad F; Das BR
    Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
    Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
    Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
    Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.
    Hsu KH; Ho CC; Hsia TC; Tseng JS; Su KY; Wu MF; Chiu KL; Yang TY; Chen KC; Ooi H; Wu TC; Chen HJ; Chen HY; Chang CS; Hsu CP; Hsia JY; Chuang CY; Lin CH; Chen JJ; Chen KY; Liao WY; Shih JY; Yu SL; Yu CJ; Yang PC; Chang GC
    PLoS One; 2015; 10(3):e0120852. PubMed ID: 25789627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
    Yousem SA; Nikiforova M; Nikiforov Y
    Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
    Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
    J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
    Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
    Suzuki M; Shiraishi K; Yoshida A; Shimada Y; Suzuki K; Asamura H; Furuta K; Kohno T; Tsuta K
    Lung Cancer; 2015 Jan; 87(1):14-22. PubMed ID: 25468202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
    Hosgood HD; Pao W; Rothman N; Hu W; Pan YH; Kuchinsky K; Jones KD; Xu J; Vermeulen R; Simko J; Lan Q
    Respir Med; 2013 Nov; 107(11):1755-62. PubMed ID: 24055406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
    Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
    Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma.
    Zheng D; Wang R; Pan Y; Zheng S; Zhang Y; Li H; Cheng C; Gong R; Li Y; Shen X; Hu H; Cai D; Cheng X; Sun Y; Chen H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1284-91. PubMed ID: 26202550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.